Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study.

PURPOSE To test in vitro whether gadolinium-based contrast agents induce fewer toxic effects on renal tubular cells than does an iodinated contrast medium at concentrations used for angiography. MATERIALS AND METHODS LLC-PK1 cells were incubated with iomeprol, gadopentetate dimeglumine, gadobenate dimeglumine, gadoterate meglumine, gadodiamide, and corresponding mannitol solutions for 24 hours at 37 degrees C in two experimental settings: measurements with equally attenuating solutions and measurements with equimolar solutions. Cytotoxicity was assessed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, trypan blue testing, and an assay to detect apoptosis and necrosis. Data were analyzed with analyses of variance and post hoc tests. RESULTS Yielding the same x-ray attenuation, iomeprol-300 and iomeprol-150 at concentrations of 2.34-18.75 mg of iodine per milliliter induced significantly (P < .001) lower inhibition of MTT conversion (74%-102% of undamaged control cells) compared with 15.63-125.00 mmol/L concentrations of the gadolinium-based agents (mean percentages of undamaged control cells: 48%-80%, 50%-87%, 60%-95%, and 56%-92% with gadopentetate dimeglumine, gadobenate dimeglumine, gadoterate meglumine, and gadodiamide, respectively). At equimolar concentrations (62.5 mmol/L), iomeprol-190 induced a mean extent of inhibition of MTT conversion (69% of undamaged control cells) similar to that induced by gadoterate meglumine (71%) and gadodiamide (70%), whereas gadopentetate dimeglumine and gadobenate dimeglumine induced stronger effects (63% and 64%, respectively; P < .001). At trypan blue testing, there were more dead cells after incubation with 125 mmol/L gadopentetate dimeglumine than after incubation with iomeprol-190 (57% vs 19%, P < .001). The 125 mmol/L gadopentetate and gadobenate formulations induced more necrosis and apoptosis than did gadoterate meglumine, gadodiamide, and iomeprol (mean percentage difference between treated and untreated control cells: for necrosis, +124%, +95%, +17%, -6%, and +3%, respectively; for apoptosis, +34%, +35%, +13%, +4%, and +5%, respectively; P < .001). CONCLUSION At angiographic concentrations, gadolinium-based contrast agents do not induce fewer cytotoxic effects on cultured renal tubular cells than does iomeprol.

[1]  D. Katz,et al.  High-dose intravenous gadolinium for renal computed tomographic angiography. , 2004, Journal of vascular and interventional radiology : JVIR.

[2]  J. Gemery,et al.  Acute renal failure after arteriography with a gadolinium-based contrast agent. , 1998, AJR. American journal of roentgenology.

[3]  Alain Duhamel,et al.  Safety and effectiveness of gadolinium-enhanced multi-detector row spiral CT angiography of the chest: preliminary results in 37 patients with contraindications to iodinated contrast agents. , 2005, Radiology.

[4]  Antonio Colombo,et al.  Contrast agent--associated nephrotoxicity. , 2003, Progress in cardiovascular diseases.

[5]  J. Weissgarten,et al.  Contrast Media Augmented Apoptosis of Cultured Renal Mesangial, Tubular, Epithelial, Endothelial, and Hepatic Cells , 2003, Investigative radiology.

[6]  M. Kuhlmann,et al.  Bioflavonoids attenuate renal proximal tubular cell injury during cold preservation in Euro-Collins and University of Wisconsin solutions. , 2003, Kidney international.

[7]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[8]  P. Taroni,et al.  Pharmacokinetics and Safety of Iomeprol in Healthy Volunteers and in Patients with Renal Impairment or End-Stage Renal Disease Requiring Hemodialysis , 2001, Investigative radiology.

[9]  R. Katzberg,et al.  High-dose clinical urography with the low-osmolality contrast agent Hexabrix: comparison with a conventional contrast agent. , 1987, Radiology.

[10]  M. Menon,et al.  Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants , 2003, Urological Research.

[11]  Teut Risler,et al.  Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  H. Thomsen,et al.  Gadolinium-containing contrast media for radiographic examinations: a position paper , 2002, European Radiology.

[13]  R. Zager,et al.  Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. , 2003, Kidney international.

[14]  A. Peer,et al.  Effects of radiologic contrast media on human endothelial and kidney cell lines: intracellular pH and cytotoxicity. , 1994, Academic radiology.

[15]  R. Gupta,et al.  Gadodiamide-based coronary angiography in a patient with severe renal insufficiency. , 2005, Journal of interventional cardiology.

[16]  R. Katholi,et al.  Proximal tubule cell response to radiographic contrast media. , 2001, American journal of physiology. Renal physiology.

[17]  Ulf Nyman,et al.  Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? , 2002, Radiology.

[18]  P. Persson,et al.  Pathophysiology of contrast medium-induced nephropathy. , 2005, Kidney international.

[19]  I. Hizoh,et al.  Radiocontrast-Induced Renal Tubular Cell Apoptosis: Hypertonic Versus Oxidative Stress , 2002, Investigative radiology.

[20]  R. Katzberg.  Contrast medium-induced nephrotoxicity: which pathway? , 2005, Radiology.

[21]  David J Spinosa,et al.  Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography. , 2002, Radiology.

[22]  H. S. Thomsen,et al.  Contrast-media-induced nephrotoxicity: a consensus report , 1999, European Radiology.

[23]  Samin K. Sharma,et al.  Effect of nonionic radiocontrast agents on the occurrence of contrast‐induced nephropathy in patients with mild‐moderate chronic renal insufficiency: Pooled analysis of the randomized trials , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[24]  C. Haller,et al.  Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  E. Christensen,et al.  Effects of Iodinated X-Ray Contrast Media on Renal Epithelial Cells in Culture , 1994, Investigative radiology.

[26]  W. Kübler,et al.  Radiocontrast-induced DNA fragmentation of renal tubular cells in vitro: role of hypertonicity. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  Christlieb Haller,et al.  The Cytotoxicity of Iodinated Radiocontrast Agents on Renal Cells In Vitro , 2004, Investigative radiology.

[28]  E. Christensen,et al.  Effects of Contrast Media on Renal Epithelial Cells in Culture , 1995, Acta radiologica. Supplementum.

[29]  E. Romagnoli,et al.  Use of a novel high-osmolar gadolinium chelate, gadobutrol, for percutaneous renal artery stenting in two patients with chronic renal failure. , 2005, International journal of cardiology.

[30]  F. S. Pereles,et al.  Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. , 2003, Journal of vascular surgery.

[31]  Henrik S. Thomsen,et al.  Gadolinium-based contrast media may be nephrotoxic even at approved doses , 2004, European Radiology.

[32]  L. Satler,et al.  Renal Artery Stenting Using Gadodiamide Arteriography in Patients with Baseline Renal Insufficiency , 2004, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[33]  T. Yano,et al.  A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. , 2005, The American journal of pathology.

[34]  T. Yano,et al.  Cyclic AMP reverses radiocontrast media-induced apoptosis in LLC-PK1 cells by activating A kinase/PI3 kinase. , 2003, Kidney international.

[35]  W. Kübler,et al.  Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers. , 1997, Cardiovascular research.

[36]  C. Baker.  Prevention of radiocontrast‐induced nephropathy , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[37]  H. Niendorf,et al.  Safety of gadolinium‐DTPA: Extended clinical experience , 1991, Magnetic resonance in medicine.

[38]  H. Fischer,et al.  Urography with low-osmolality contrast media: comparative urinary excretion of Iopamidol, Hexabrix, and diatrizoate. , 1982, Investigative radiology.

[39]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[40]  D. Roberts,et al.  Gadolinium arteriography complicated by acute pancreatitis and acute renal failure. , 2001, Journal of vascular and interventional radiology : JVIR.

[41]  G. Rosati.  Clinical pharmacology of iomeprol. , 1994, European journal of radiology.

[42]  E. M. Watkin,et al.  Hemodialysis and Iopamidol Clearance after Subclavian Venography , 1993, Investigative radiology.

[43]  T. Yano,et al.  A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. , 2004, Kidney international.

[44]  Mahmoud Torabinejad,et al.  Evaluation of cytotoxicity of MTAD using the MTT-tetrazolium method. , 2003, Journal of endodontics.

[45]  C. Badiola.  Use of a Mixture of Gadolinium and Iodinated Contrast for Angiography , 2004, CardioVascular and Interventional Radiology.

[46]  Geoffrey D Rubin,et al.  Atherosclerotic Vascular Disease Conference: Writing Group IV: imaging. , 2004, Circulation.

[47]  R. Solomon.  The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. , 2005, Kidney international.

[48]  H. Schild,et al.  Actual clinical use of gadolinium-chelates for non-MRI applications , 2004, European Radiology.

[49]  G. Condorelli,et al.  Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. , 2005, Kidney international.

[50]  V. Runge,et al.  Contrast Agents for Magnetic Resonance Imaging: Safety Update , 2003, Topics in magnetic resonance imaging : TMRI.

[51]  M. Uder,et al.  Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. , 2005, Radiology.